| pubmed-article:2175673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2175673 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:2175673 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:2175673 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:2175673 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2175673 | pubmed:dateCreated | 1991-2-7 | lld:pubmed |
| pubmed-article:2175673 | pubmed:abstractText | Cytotoxic T lymphocytes from healthy donors can be expanded to high numbers from the peripheral blood using combinations of anti-CD3 and anti-CD28 monoclonal antibodies (mAb). We investigated whether these antibodies could also be used to induce outgrowth of tumour-infiltrating lymphocytes (TIL) from tumour tissue. In the initiation phase of TIL culture immobilized anti-CD3 antibodies together with anti-CD28 mAb and low-dose interleukin-2 induced a rapid expansion of T cells from various human tumour tissues. The cultured cells showed high levels of cytotoxic T lymphocyte activity, but low levels of lymphokine-activated killer cell activity were generated. This study shows that TIL can be efficiently expanded from tumour tissue by combinations of anti-CD3 and anti-CD28 antibodies. This protocol for cell expansion in vitro may substantially reduce the time required to reach sufficient numbers of TIl for re-infusion to the patient. | lld:pubmed |
| pubmed-article:2175673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2175673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2175673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2175673 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:2175673 | pubmed:author | pubmed-author:van LierR ARA | lld:pubmed |
| pubmed-article:2175673 | pubmed:author | pubmed-author:FigdorC GCG | lld:pubmed |
| pubmed-article:2175673 | pubmed:author | pubmed-author:NijhuisE WEW | lld:pubmed |
| pubmed-article:2175673 | pubmed:author | pubmed-author:vd Wiel-van... | lld:pubmed |
| pubmed-article:2175673 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2175673 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:2175673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2175673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2175673 | pubmed:pagination | 245-50 | lld:pubmed |
| pubmed-article:2175673 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:meshHeading | pubmed-meshheading:2175673-... | lld:pubmed |
| pubmed-article:2175673 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2175673 | pubmed:articleTitle | Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. | lld:pubmed |
| pubmed-article:2175673 | pubmed:affiliation | Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, University of Amsterdam. | lld:pubmed |
| pubmed-article:2175673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2175673 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2175673 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2175673 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2175673 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2175673 | lld:pubmed |
